首页> 中文期刊>中国药房 >尼美舒利联合奥沙利铂对食管癌大鼠移植瘤生长及免疫功能的影响

尼美舒利联合奥沙利铂对食管癌大鼠移植瘤生长及免疫功能的影响

     

摘要

OBJECTIVE:To study the effects of nimesulide combined with oxaliplatin on transplanted tumor growth and im-mune function of rats with esophageal cancer. METHODS:Rats were randomly divided into model group(intragastrically given So-dium carboxymethyl cellulose solution+intravenously given 5% Glucose injection in tail),nimesulide group(intragastrically given 20 mg/kg),oxaliplatin group(intravenously given 13.6 mg/kg in tail)and combination group,10 in each group. Esophageal can-cer Eca109 cells were subcutaneously injected to develop transplanted tumor model. After modeling,rats in each group received rel-evant medicines by corresponding ways,once a day for ig,once every 4 d for iv in tail. Rats were sacrificed after 8 weeks,tumor volume and quality of rats were measured,tumor inhibition rate was calculated,and contents of tumor markers(CEA,CYFRA21-1,SCCAg),percentages of immune cells(CD3+,CD4+,CD8+T cells and NK cell)in peripheral blood were detected. RESULTS:Compared with model group,tumor volume and quality in other 3 groups were decreased (P<0.05);contents of tumor markers were decreased (P<0.05). Percentages of CD3+,CD4+ T cells and NK cell in nimesulide group were increased,percentages of CD8+T cell was decreased(P<0.05). Percentages of CD3+,CD4+T cells and NK cell in oxaliplatin group and combination group were decreased,percentages of CD8+ T cell was increased(P<0.05). Compared with nimesulide group and oxaliplatin group,tu-mor inhibition rate in combination group was increased(P<0.05);contents of tumor markers were decreased(P<0.05);percent-ages of immune cells were lower than nimesulide group and higher than oxaliplatin group(P<0.05). CONCLUSIONS:Nimesulide can enhance the oxaliplatin's antitumor effect on esophageal cancer,and decrease its inhibition degree on immune functions.%目的:研究尼美舒利联合奥沙利铂对食管癌大鼠移植瘤生长及免疫功能的影响.方法:将大鼠随机分为模型组(ig羧甲基纤维素钠溶液+尾iv 5%的葡萄糖注射液)、尼美舒利组(ig 20 mg/kg)、奥沙利铂组(尾iv 13.6 mg/kg)及联用组,每组10只,ih食管癌Eca109细胞建立移植瘤模型.建模成功后各组大鼠按相应方式给予相应药物,ig每天1次,尾iv每4 d 1次.8周后处死大鼠,测量各组大鼠瘤体积和瘤质量,计算抑瘤率,检测血清中肿瘤标志物(CEA、CYFRA21-1、SCCAg)含量、外周血中免疫细胞(CD3+、CD4+、CD8+T细胞和NK细胞)百分比.结果:与模型组比较,其余3组大鼠瘤体积和瘤质量减小(P<0.05);肿瘤标志物含量减少(P<0.05);尼美舒利组大鼠CD3+、CD4+T细胞和NK细胞百分比增高,CD8+T细胞百分比降低(P<0.05);奥沙利铂组和联用组大鼠CD3+、CD4+T细胞和NK细胞百分比降低,CD8+T细胞数量百分比增高(P<0.05).与尼美舒利组和奥沙利铂组比较,联用组大鼠抑瘤率增加(P<0.05),肿瘤标志物含量减少(P<0.05),免疫细胞百分比较尼美舒利组降低、较奥沙利铂组增高(P<0.05).结论:尼美舒利能增强奥沙利铂对食管癌的抑瘤作用,降低奥沙利铂对大鼠免疫功能的抑制程度.

著录项

相似文献

  • 中文文献
  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号